Stockscreener 앱 받기
288.41
3.60%
10.01
시간 외 거래:
288.56
0.15
+0.05%
전일 마감가:
$278.40
열려 있는:
$282.79
하루 거래량:
1.44M
Relative Volume:
1.14
시가총액:
$38.51B
수익:
$4.29B
순이익/손실:
$577.22M
주가수익비율:
68.53
EPS:
4.2086
순현금흐름:
$641.34M
1주 성능:
+6.28%
1개월 성능:
-1.02%
6개월 성능:
-17.50%
1년 성능:
-11.20%
1일 변동 폭
$281.23
$290.47
1주일 범위
$262.21
$290.47
52주 변동 폭
$262.21
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
288.41 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
490.39 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
695.18 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.23 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.86 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Why Alnylam’s Best Quarter Ever Didn’t Come With a Richer Valuation - Yahoo Finance
Did Alnylam’s Alzheimer’s Pipeline Advances Just Shift Alnylam Pharmaceuticals' (ALNY) Investment Narrative? - simplywall.st
Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning - Quiver Quantitative
Alnylam Pharmaceuticals Inc (ALNY) Institutional Confidence - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alnylam Pharmaceuticals (ALNY) Could Be 38% Undervalued After Mivelsiran Trial Progress - simplywall.st
BR:A1LN34 Stock Latest News - TipRanks
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo Finance Australia
ALNY Stock Price TodayAlnylam Pharmaceuticals Inc News, Charts, Retail Sentiment - Stocktwits
Alnylam stock trades steady as RNAi pipeline advances and cash position supports development - Ad-hoc-news.de
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
ALNY Maintains Overweight by JP Morgan -- Price Target Lowered t - GuruFocus
Alnylam Pharmaceuticals Price Target Cut to $400.00/Share From $420.00 by JP Morgan - Moomoo
ALNY|Alnylam Pharmaceuticals Inc|Price:269.400|Chg%:+0.660 - TradingKey
US2043QAC1 Bond Profile — Key Metrics - TradingView
Biomarker Collaboration and Licensing Deals Report 2016-2026Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Q2 2024 earnings summary - Quartr
Alnylam Stock And 2 US Health Care Names With Earnings In Focus - simplywall.st
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Look At Its 62.57% Potential Upside - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Status update Summary - Quartr
Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses - simplywall.st
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com - Investing.com South Africa
Alnylam slips as recent analyst target cuts appear to overshadow pipeline updates ahead of earnings - Quiver Quantitative
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD - Investing.com
Why is Alnylam Pharmaceuticals stock down 3.8% today? - Traders Union
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200 - GlobeNewswire Inc.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), Alnylam Pharma (ALNY) and Elevance Health (ELV) - The Globe and Mail
Alnylam Pharmaceuticals (ALNY) Proxy filing Summary - Quartr
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth - ChartMill
Liquidity Mapping Around (ALNY) Price Events - Stock Traders Daily
Alnylam schedules conference call on second-quarter 2026 results - Bitget
Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - Moomoo
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - BioSpace
Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak - Trefis
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY) - Seeking Alpha
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - The National Law Review
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease - BioSpace
ALNY Maintained by B of A Securities -- Price Target Lowered to $410 - GuruFocus
Morgan Stanley Raises its Price Target on Alnylam (ALNY) - Yahoo Finance
BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating - Moomoo
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says - Moomoo
Stifel reiterates Buy rating on Alnylam stock amid trial debate By Investing.com - Investing.com Canada
BofA cuts Alnylam stock price target on conservative outlook By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock - ChartMill
Alnylam Pharmaceuticals Price Target Raised to $485.00/Share From $470.00 by HC Wainwright & Co. - Moomoo
ALNY Maintains Rating by Truist Securities -- Price Target Lowered to $410 - GuruFocus
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
2.24%
1.40%
자본화:
|
볼륨(24시간):